DIGITAL PROTEOMICS LLC
Biotech · Private
Single-chain antibodies derived from camelid immune repertoires for therapeutic development
- Grants
- $2.9M
- 12 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Valens-Poly Sequencing Polyclonal Antibodies for Drug Discovery | $334,446 | |
| Federal grant | Department of Health and Human Services · Phase II · Valens-Poly Sequencing Polyclonal Antibodies for Drug Discovery | $318,449 | |
| Federal grant | Department of Health and Human Services · Phase II · An integrated transcriptomic and proteomic approach to antibody sequencing and repertoire characterization | $388,404 | |
| Federal grant | Department of Health and Human Services · Phase I · Quorum: natural product discovery via mass spectrometry and molecular networking | $193,466 | |
| Federal grant | Department of Health and Human Services · Phase II · An integrated transcriptomic and proteomic approach to antibody sequencing and repertoire characterization | $383,862 | |
| Federal grant | Department of Health and Human Services · Phase I · Alicanto: Proteogenomic discovery of single chain antibodies in llama | $170,108 | |
| Federal grant | Department of Health and Human Services · Phase II · An integrated transcriptomic and proteomic approach to antibody sequencing and repertoire characterization | $114,553 | |
| Federal grant | Department of Health and Human Services · Phase I · Immune repertoire sequencing: error correction, analysis, and visualization on the cloud | $217,313 | |
| Federal grant | Department of Health and Human Services · Phase II · Alicanto: Proteogenomic discovery of single chain antibodies in llama | $604,571 | |
| Federal grant | Department of Health and Human Services · Phase II · Quorum: glycopeptide discovery via mass spectrometry and spectral networking | $146,827 | |
| Federal grant | Department of Health and Human Services · Phase I · Intelligent in silico antibody library design and optimization for therapeutic use | $24,590 | |
| Federal grant | Department of Health and Human Services · Phase II · Software for sequencing human antibody proteins from polyclonal immune responses | $23,935 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1242 | Antag Therapeutics | — | — |
| 1243 | DEKK-TEC, INC. | — | — |
| 1244 | QX Therapeutics, Inc. | — | — |
| 1245 | DIGITAL PROTEOMICS LLC | — | — |
| 1246 | New England Discovery Partners, LLC | — | — |
| 1247 | TARGUT BIOTECHNOLOGIES INC. | — | — |
| 1248 | SignalRx Pharmaceuticals Inc. | — | $250K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.